Weight-Loss drug wegovy tested as Hair-Pulling treatment
NCT ID NCT07282769
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a weekly injection of semaglutide (Wegovy), a drug used for weight loss and diabetes, can help people with trichotillomania (hair-pulling disorder). Ten adults aged 18-75 with daily hair pulling will receive the drug for several weeks. Researchers will measure changes in hair-pulling severity using a standard rating scale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
semaglutide (Wegovy)
What this could lead to
If it works, this could point toward a new treatment option for trichotillomania, reducing the urge to pull hair.
What could go wrong
This is a very small, early-phase trial with only 10 people and no placebo group, so results may not be reliable or generalizable. Semaglutide can cause nausea, vomiting, and other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRICHOTILLOMANIA (HAIR-PULLING DISORDER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••